Aethlon Medical Inc (AEMD)

[thomasichim]

Cancer immunotherapy is the future of oncology...aemd has issued patent on the only
Checkpoint inhibitor medical device...I know cause I wrote part of the patent ...cancer Exosome
Removal is way of future and with issued patent the Big Pharma will eventually license .... If you have questions email me directly [e-mail] and cause I don't work for the company I can talk anything I want !! Lol

Peer reviewed paper with me as fist author 79 citations https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-6-37

Issued US patent http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=4&f=G&l=50&co1=AND&d=PTXT&s1=Ichim.INNM.&OS=IN/Ichim&RS=IN/Ichim

Read the issued claims and tell me that aemd does not kick ass

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A method of capturing an exosome from a patient on a surface that comprises a lectin, said method comprising: identifying a patient for exosome capture and contacting an exosome from said patient with a surface that comprises a lectin thereby capturing said exosome.

2. The method of claim 1, wherein the surface is selected from the group consisting of: silica gel, dextran, agarose, nylon polymers, polymers of acrylic acid, silica gel, dextran, agarose, nylon polymers, polymers of acrylic acid, co-polymers of ethylene and maleic acid anhydride, aminopropylsilica, aminocelite, glass beads, and silicate containing diatomaceous earth.

3. The method of claim 1, wherein the surface is a bead.

4. The method of claim 1, wherein the surface is a filter.

5. The method of claim 1, wherein the lectin is selected from the group consisting of GNA, NPA, Conconavalin A, phytohemagluttanin, and cyanovirin.

6. The method of claim 1, wherein the patient has cancer.

7. The method of claim 1, wherein the patient has spontaneous T cell apoptosis.

8. The method of claim 1, wherein the exosome is from whole blood or components thereof.

9. A method of capturing an exosome from a patient comprising: contacting an exosome from said patient with an affinity device that comprises an affinity absorbent comprising a lectin thereby capturing said exosome on the affinity absorbent.

10. The method of claim 9, wherein the affinity absorbent comprises silica gel, dextran, agarose, nylon polymers, polymers of acrylic acid, silica gel, dextran, agarose, nylon polymers, polymers of acrylic acid, co-polymers of ethylene and maleic acid anhydride, aminopropylsilica, aminocelite, glass beads, or silicate containing diatomaceous earth.

11. The method of claim 9, wherein the affinity absorbent is a bead.

12. The method of claim 9, wherein the affinity absorbent is a filter.

13. The method of claim 9, wherein the lectin is selected from the group consisting of GNA, NPA, Conconavalin A, phytohemagluttanin, and cyanovirin.

14. The method of claim 9, wherein the patient has cancer.

15. The method of claim 9, wherein the patient has spontaneous T cell apoptosis.

16. The method of claim 9, wherein the exosome is from whole blood or components thereof.

17. The method of claim 9, further comprising selecting a patient to have an exosome captured by said affinity device.